Platelet rich plasma (PRP) is obtained from blood. It has higher platelet concentration, that is, more than the normal values. The plasma rich platelets are obtained by centrifuging the human blood and thus separating it. Platelets aid in blood clotting and improve the healing of muscles, ligaments, & tendons.
The growth of global platelet rich plasma market is expected to be mainly driven by factors such as the escalating occurrences of sports injuries, the rising usage of platelet-rich plasma in numerous therapeutic areas, and cumulative count of surgical & cosmetic procedures. The other key factors propelling the market expansion include increase in elderly population, rise in cognizance about PRP therapies, and technological advancements. Furthermore, the market is also expected to witness lucrative opportunities during the forecast period owing to increasing R&D activities. To cite, scientists from Charles University, Czech Republic, and Institute of Experimental Medicine of the Czech Academy of Sciences, in September 2020, stated development of an easy delivery system to lengthen the impacts of the bioactive molecules discharged from platelets.
The global platelet rich plasma market can be bifurcated based on origin, type, application, end-user, and region. The global market, by origin, can be segregated into homologous platelet rich plasma, autologous platelet rich plasma, and allogeneic platelet rich plasma. The global market, on the basis of type, can be classified into leukocyte-rich platelet-rich plasma, pure platelet-rich plasma, leukocyte-rich platelet-rich fibrin, and pure platelet-rich fibrin. The global market, by end-user, can be categorized into orthopedic clinics, hospitals & clinics, research institutions, dermatology clinics, and others. The global market, on the basis of application, is segmented into cosmetic surgery, orthopedics, dental, dermatology, nerve injury, cardiac muscle injury, and others.
The global platelet rich plasma market is projected to be dominated by North America region during the forecast period. This regional expansion can be credited to numerous factors such as the increasing incidence of numerous disorders like arthritis, enhanced regulatory framework, deep-rooted healthcare infrastructure, and support by government. Likewise, Asia Pacific is anticipated to witness lucrative growth in the market during the upcoming period on account of the growing spending in healthcare infrastructure by government & private organizations, escalating population base with orthopedic disorders & chronic wounds, rising expenditure in healthcare, along with the growth in the network of prominent players in this region.
The key players functional in the global platelet rich plasma market consist of Stryker Corporation, Arthrex, Inc., Zimmer Biomet Holdings Inc., Johnson and Johnsons Ltd., Glofinn Oy, Terumo Corporation, Regen Lab S.A., Medira Ltd., Generex Biotechnology Corporation, CollPlant, and Estar Technologies Ltd.